Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)

Sponsor
Lung Cancer Group Cologne
Study ID
NCT00568841
Phase
PHASE2
Status
Unknown

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • erlotinib — DRUG
    erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
  • FDG-/FLT-PET — PROCEDURE

Study Details

This is a Phase-II Study to evaluate the accuracy of Fluorodeoxyglucose-/Fluorothymidine-Positron Emission Tomography (FDG-/FLT-PET) analyses for early prediction of non-progression in patients with non-small-cell lung cancer (NSCLC) treated with Erlotinib.

Key Dates

First listed
Dec 6, 2007
Start date
Oct 31, 2007
Status verified
Sep 2009
Primary completion
Dec 31, 2009
Completion
Dec 31, 2009

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: 1

Primary Outcome Measure

To evaluate the accuracy of FDG-/FLT-PET analyses for early prediction of non-progression in patients with NSCLC treated with Erlotinib [ Time Frame: 34 months ]

Related Studies